Showing 123 results
-
Media Release /Novartis Healthcare Philippines was recognized by the National Committee for Sight Preservation (NCSP) for the company’s support to the NCSCP “Maging MATAlino”…
-
Media Release /Novartis has made substantial contributions to support the Philippine economy and improve health outcomes of Filipinos. “We are committed to helping strengthen the Philippine economy. In 2021,…
-
Media Release /The Philippine Food and Drug Administration (FDA) has approved ribociclib for the treatment of metastatic breast cancer. Ribociclib in combination with an aromatase inhibitor or fulvestrant…
-
Media Release /The APPIS Innovator Program enables patient organizations across Asia Pacific, Middle East and Africa (APMA) to grow and scale existing patient programs. Winners receive financial support,…
-
Media Release /The Philippine Food and Drug Administration (FDA) has approved brolucizumab for the treatment of neovascular (wet) age-related macular degeneration (AMD). Wet AMD is the leading cause of severe…
-
Media Release /Psoriasis causes significant physical, emotional and psychological burden on children and adolescents. Fortunately, effective treatment options are available and parents can take steps to help…
-
Media Release /Genetic mutations affect breast cancer prognosis, making every patient unique. It is important for patients to get tested to find out the specific mutation, and help doctors develop a personalized…
-
Media Release /The Philippine Food and Drug Administration (FDA) has approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human…
-
Media Release /Filipinos with moderate-to-severe psoriasis experience significant negative impact on their quality of life, psychological and emotional wellbeing, and productivity. This was revealed…
-
Media Release /Stakeholder officials signed the formal agreement to implement the Novartis PIK3CA Testing Program for advanced Breast Cancer patients. Photo shows (from left): Ms…
